The accelerator will connect AbbVie scientists with the lab of Kyriacos Nicolaou, pioneer of an approach for replicating natural molecules with cancer-fighting qualities.
Rice University has joined forces with pharmaceutical firm AbbVie to launch the KC Nicolaou Research Accelerator aimed at the development of cytotoxic drugs to combat cancer.
The accelerator will connect AbbVie scientists with the laboratory of Kyriacos Nicolaou, the Harry C. and Olga K. Wiess professor of chemistry at Rice, whose primary disciplines are organic synthesis and chemical biology.
Nicolaou’s lab has created an approach to replicate natural molecules with anti-cancer qualities as part of enhanced oncological agents,…
